Molly E DeWitt-Foy1,2, Bradley C Gill3,4,5, James C Ulchaker3,4. 1. Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Mail Stop Q10-1 9500 Euclid Avenue, Cleveland, OH, 44195, USA. dewittm@ccf.org. 2. Lerner College of Medicine, Education Institute, Cleveland Clinic, Mail Stop NA21 9500 Euclid Avenue, Cleveland, OH, 44195, USA. dewittm@ccf.org. 3. Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Mail Stop Q10-1 9500 Euclid Avenue, Cleveland, OH, 44195, USA. 4. Lerner College of Medicine, Education Institute, Cleveland Clinic, Mail Stop NA21 9500 Euclid Avenue, Cleveland, OH, 44195, USA. 5. Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Abstract
PURPOSE OF REVIEW: To provide an economic context within which to consider treatment options for benign prostatic hyperplasia (BPH). To this end, this review provides a comparison of the costs of combination medical therapy, operative treatment, and office-based therapies for BPH from a payer perspective. RECENT FINDINGS: Analysis of Medicare charges from the authors' institution, as well as local retail costs of medication, demonstrated a wide range in costs of commonly used BPH treatments. In this study, interventions for BPH reached cost equivalence with combination medical therapy within 6 months to 8 years. A myriad of options for managing men with symptomatic BPH exist. It is prudent not only to consider surgeon preference and patient-specific factors when selecting a treatment but also to understand the economic impact different BPH therapies confer.
PURPOSE OF REVIEW: To provide an economic context within which to consider treatment options for benign prostatic hyperplasia (BPH). To this end, this review provides a comparison of the costs of combination medical therapy, operative treatment, and office-based therapies for BPH from a payer perspective. RECENT FINDINGS: Analysis of Medicare charges from the authors' institution, as well as local retail costs of medication, demonstrated a wide range in costs of commonly used BPH treatments. In this study, interventions for BPH reached cost equivalence with combination medical therapy within 6 months to 8 years. A myriad of options for managing men with symptomatic BPH exist. It is prudent not only to consider surgeon preference and patient-specific factors when selecting a treatment but also to understand the economic impact different BPH therapies confer.
Authors: Laura Knight; Megan Dale; Andrew Cleves; Charlotte Pelekanou; Rhys Morris Journal: Appl Health Econ Health Policy Date: 2022-07-18 Impact factor: 3.686
Authors: Maria M Wertli; Brigitta Zumbrunn; Pascal Weber; Alan G Haynes; Radoslaw Panczak; Arnaud Chiolero; Nicolas Rodondi; Drahomir Aujesky Journal: PLoS One Date: 2021-07-22 Impact factor: 3.240
Authors: Marta Tenuta; Maria G Tarsitano; Paola Mazzotta; Livia Lucchini; Franz Sesti; Giorgio Fattorini; Carlotta Pozza; Valerio Olivieri; Fabio Naro; Daniele Gianfrilli; Andrea Lenzi; Andrea M Isidori; Riccardo Pofi Journal: Andrology Date: 2020-03-16 Impact factor: 3.842